Disc Medicine legal chief sells 7,500 shares after option exercise

Disc Medicine Chief Legal Officer Rahul Khara reported an exercise-and-sell transaction in company common stock.

Rhea-AI Filing Summary

Disc Medicine Chief Legal Officer Rahul Khara reported an exercise-and-sell transaction in company common stock. On June 18, 2026, he exercised stock options to acquire 7,500 shares at an exercise price of $14.69 per share, then sold 7,500 shares in open-market trades at weighted average prices between about $69.35 and $71.81. The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, he directly holds 52,173 shares of Disc Medicine common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,500 shares ($416K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Khara Rahul

Role Chief Legal Officer

Sold 7,500 shs ($527K)

Approx. gross sale proceeds $527K

Approx. exercise cost $110K

Approx. pre-tax spread $416K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	7,500	$0.00	$0.00
Exercise	Common Stock	7,500	$14.69	$110K
Sale	Common Stock	5,400	$69.9423	$378K
Sale	Common Stock	1,600	$70.7257	$113K
Sale	Common Stock	500	$71.622	$36K

Holdings After Transaction: Stock Option (Right to Buy) — 57,304 contracts (Direct); Common Stock — 52,173 shares (Direct)

Footnotes (5)

1. F1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.35 to $70.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.40 to $71.38, inclusive.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.45 to $71.81, inclusive.
5. F5. The shares underlying this option are fully vested and exercisable as of the date hereof.

Key Figures

Shares sold: 7,500 shares Sale prices: $69.35–$71.81 per share Weighted average prices: $69.9423, $70.7257, $71.6220 +4 more

7 metrics

Shares sold 7,500 shares Open-market sales of common stock on June 18, 2026

Sale prices $69.35–$71.81 per share Price ranges for multiple sale transactions on June 18, 2026

Weighted average prices $69.9423, $70.7257, $71.6220 Three reported weighted average sale prices for common stock

Options exercised 7,500 shares Stock option exercise converting into common stock

Option exercise price $14.69 per share Exercise price for 7,500 stock options

Shares owned after 59,673 shares Direct common stock holdings following June 18, 2026 transactions

Net share change -7,500 shares NetBuySellShares from transactionSummary (net-sell direction)

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open-market sale financial

"Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Disc Medicine (IRON) insider Rahul Khara report in this Form 4?

Rahul Khara reported exercising stock options and selling common shares of Disc Medicine. He exercised 7,500 options at $14.69 per share, then sold 7,500 shares in open-market trades under a Rule 10b5-1 plan, and now directly holds 59,673 shares.

How many Disc Medicine (IRON) shares did Rahul Khara sell and at what prices?

He sold a total of 7,500 Disc Medicine common shares. The filing shows three open-market sale transactions on June 18, 2026 at weighted average prices of $69.9423, $70.7257 and $71.6220 per share, within price ranges between $69.35 and $71.81.

What stock options did Rahul Khara exercise in Disc Medicine (IRON)?

He exercised stock options covering 7,500 shares of Disc Medicine common stock. The options had an exercise price of $14.69 per share and were fully vested and exercisable as of the transaction date, according to the disclosure in the Form 4 footnotes.

Was Rahul Khara’s Disc Medicine (IRON) share sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan adopted on March 19, 2026. Such plans allow insiders to pre-schedule trades, which can make transaction timing less reflective of their short-term market views.

How many Disc Medicine (IRON) shares does Rahul Khara own after these transactions?

After completing the June 18, 2026 transactions, Rahul Khara directly owns 59,673 shares of Disc Medicine common stock. This figure reflects his position after exercising 7,500 options and selling 7,500 shares in the open market as reported in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 05:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khara Rahul

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		M(1)		7,500	A	$14.69	59,673	D
Common Stock	06/18/2026		S(1)		5,400	D	$69.9423(2)	54,273	D
Common Stock	06/18/2026		S(1)		1,600	D	$70.7257(3)	52,673	D
Common Stock	06/18/2026		S(1)		500	D	$71.622(4)	52,173	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.69	06/18/2026		M(1)			7,500	(5)	02/07/2032	Common Stock	7,500	$0	57,304	D

Explanation of Responses:

1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.35 to $70.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.40 to $71.38, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.45 to $71.81, inclusive.

5. The shares underlying this option are fully vested and exercisable as of the date hereof.

	By: /s/ Rahul Khara	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)